- Home
- OBAI vs AEON Comparison
OBAI vs AEON Comparison
Compare OBAI & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.43
HOLD
Current Price
$1.04
Company Overview
Basic Information| Metric | OBAI | AEON |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 26.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OBAI | AEON |
|---|---|---|
| Price | $1.43 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 543.4K | 46.5K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $0.38 |
| 52 Week High | $19.95 | $1.45 |
Technical Indicators
Market Signals| Indicator | OBAI | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 9.26 | 42.53 |
| Support Level | N/A | $1.01 |
| Resistance Level | $2.15 | $1.12 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.41 | -0.01 |
| Stochastic Oscillator | 11.76 | 8.70 |
Price Performance
Historical Comparison OBAI
AEON
About OBAI TG-17 Inc. Common Stock
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.